RhumbLine Advisers
BNGO icon

RhumbLine Advisers’s Bionano Genomics BNGO Stock Holding History

RhumbLine Advisers’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20
Closed -$832 – 4212
2024
Q2 		$832 Hold
20
– – ﹤0.01% 4255
2024
Q1 		$1.36K Hold
20
– – ﹤0.01% 4121
2023
Q4 		$2.32K Hold
20
– – ﹤0.01% 4083
2023
Q3 		$3.72K Sell
20
-28
-58% -$7.34K ﹤0.01% 4030
2023
Q2 		$17.7K Sell
48
-752
-94% -$340K ﹤0.01% 3832
2023
Q1 		$533K Buy
800
+29
+4% +$25.8K ﹤0.01% 2403
2022
Q4 		$675K Buy
771
+11
+1% +$13.8K ﹤0.01% 2326
2022
Q3 		$835K Buy
760
+61
+9% +$80.6K ﹤0.01% 2240
2022
Q2 		$579K Buy
699
+198
+40% +$204K ﹤0.01% 2416
2022
Q1 		$775K Buy
501
+11
+2% +$14.8K ﹤0.01% 2232
2021
Q4 		$879K Sell
490
-4
-0.8% -$10.7K ﹤0.01% 2261
2021
Q3 		$1.63M Buy
494
+12
+2% +$42K ﹤0.01% 2008
2021
Q2 		$2.12M Buy
+482
New +$1.9M ﹤0.01% 1924

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CAM
Carret Asset Management New York $1.02B AUM 26.95% 1-Year Est. Return

RhumbLine Advisers's BNGO Position: Q3 2024 in Review

RhumbLine Advisers sold out of Bionano Genomics (BNGO) in Q3 2024, closing a stake of 20 shares — an estimated $832 sold.

RhumbLine Advisers first reported a position in BNGO in Q2 2021 and held it in 13 quarters. The position peaked at $2.12M in Q2 2021. 47 funds tracked by Wall St. Rank hold BNGO as of Q3 2024.

  • RhumbLine Advisers reported no remaining Bionano Genomics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 20 Bionano Genomics shares in Q3 2024, an estimated $832.
  • RhumbLine Advisers first reported a position in Bionano Genomics in Q2 2021 and held it in 13 quarters.
  • RhumbLine Advisers's Bionano Genomics position peaked at $2.12M in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.